Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc > Claritas Concept

<< Previous

Bullboard Posts

Next >>

Comment by Scottyon Feb 15, 2021 1:12am

199 Views

Post# 32567008

RE: Claritas Concept

We have a license (correct spelling) at the cost of millions of dollars for an unproven drug that needs further millions of dollars (funded by us through dilution) to fund the studies needed to prove it's efficacy for its privately owned company. Tell me more about how KLY or whatever Rob apparently renamed the company (probably try and shed it's horrible history from new investors) will benefit on a hard maybe? Calm down. I'm expecting to be seriously underwhelmed at the highly anticipated NR if/when this get released.

<< Previous

Bullboard Posts

Next >>

This junior mining stock offers billions in market exposure